clinical
-
Telormedix’s TMX-101 exhibits high safety in phase I/II for non-muscle invasive bladder cancer
Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.
clinical | 04 May 2012
-
Aslan Pharmaceuticals selects PharmaNet/i3 as partner for oncology development
Aslan Pharmaceuticals has selected PharmaNet/i3 as a partner supporting the development of their oncology portfolio in Asia.
clinical | 02 May 2012
-
INCIVEK is well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens
Phase 2 study of INCIVEK combination regimen shows 74 percent of people co-infected with hepatitis C, HIV had undetectable hepatitis C virus 12 weeks after treatment ended.
clinical | 30 April 2012
-
Quintiles, Biofund to expand clinical development capabilities in Russia
Russian venture company (RVC), Biofund, and Quintiles announced an agreement to support expansion of clinical development services within the Russian Federation, the world’s ninth most populous country.
clinical | 13 April 2012
-
Greenphire, Merge Healthcare form partnership to integrate clinical payment and EDC platforms
Greenphire has formed an exclusive partnership with the clinical trials division of Merge Healthcare to offer integrated functionality between Merge’s EDC technology and Greenphire’s eClinicalGPS site and vendor payment management technology.
clinical | 15 March 2012
-
Molecular Profiles invests in new facility to increase manufacturing capabilities for clinical trials
Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.
clinical | 19 January 2012
-
US government HIV/AIDS clinical trial sites to accelerate completion of Phase III TB drug trial
The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.
clinical | 09 January 2012
-
ICON names global head of clinical research services
ICON announced that Dr Steve Cutler will join the company as group president, clinical research services. Dr Cutler has over 23 years’ experience within the pharmaceutical and CRO industry and joins ICON from Kendle where he held the position of chief executive officer, having previously served as Kendle’s chief operating officer.
clinical | 29 November 2011
-
Ziopharm Oncology presents preclinical data for Darinaparsin at AACR-NCI-EORTC meeting
Ziopharm Oncology announced that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In addition to company authors, the studies included authors Joseph R Bertino MD and Nitu Bansal PhD from UMDNJ-The Cancer Institute of New Jersey.
clinical | 23 November 2011
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
clinical | 18 November 2011
